Opinion

Video

Approved Therapies for Steroid-Refractory Chronic GvHD

Author(s):

Hana Safah, MDCorey S. Cutler, MD, MPH, FRCPC

Hematologist-oncologists give an overview of the 3 approved treatment options for patients with steroid-refractory chronic GvHD—ruxolitinib, ibrutinib, and belumosudil—and highlight the REACH3 and ROCKstar studies.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Sara M. Tolaney, MD, MPH
Justin M. Watts, MD
A panel of 3 experts on CLL
A panel of 3 experts on CLL
2 KOLs are featured in this program.
2 KOLs are featured in this program.
2 KOLs are featured in this series
2 KOLs are featured in this series
Mazyar Shadman, MD, MPH
Related Content
Mark R. Litzow, MD
July 24th 2024

Blinatumomab Plus Consolidation Chemotherapy Extends OS in MRD– B-Cell Precursor ALL

Andrew J. Wagner, MD, PhD, medical director, Ambulatory Oncology, senior physician, Dana-Faber Cancer Institute; associate professor, medicine, Harvard Medical School
March 28th 2024

Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa

Adrienne G. Waks, MD
July 24th 2024

Tucatinib Retains its Role in HER2+ Metastatic Breast Cancer, Prompting Questions of T-DXd’s Potential Takeover in the First Line

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

FDA
July 23rd 2024

FDA Accepts Resubmission of BLA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

Adrienne G. Waks, MD, of Dana-Farber Cancer Institute
July 23rd 2024

Neoadjuvant Therapy Selection: Are Abbreviated Regimens an Option in HER2+ Breast Cancer?